Risk of dementia after charcoal-burning suicide attempts: a nationwide cohort study in Taiwan

Shan-Yueh Chang, ^{1,2} Wu-Chien Chien, ^{3,4,5} Chi-Hsiang Chung, ^{4,5,6} Hsin-An Chang, ^{7,8} Yu-Chen Kao, ^{7,8,9} Hui-Wen Yeh, ^{7,10,11,12} Yu-Ching Chou, ⁵ Chung-Kan Peng, ^{1,13} Chih-Hao Shen, ^{1,2,13} Nian-Sheng Tzeng^{7,8}

ABSTRACT

► Additional material is published online only. To view please visit the journal online (http://dx.doi.org/10. 1136/jim-2018-000759).

For numbered affiliations see end of article.

Correspondence to

Dr. Nian-Sheng Tzeng, Department of Psychiatry, Tri-Service General Hospital, National Defense Medical Center, Tapei 144, Taiwan; pierrens@mail.ndmctsgh. edu.tw

Accepted 15 May 2018

Check for updates

To cite: Chang S-Y, Chien W-C, Chung C-H, et al. J Investig Med Epub ahead of print: [please include Day Month Year]. doi:10.1136/jim-2018-000759 This study aimed to investigate the association between charcoal-burning suicide attempts and the risk of developing dementia. A nationwide, matched cohort, population-based study enrolled a total of 4103 patients with newly diagnosed charcoalburning suicide attempts, between 2000 and 2010, which were selected from the National Health Insurance Research Database of Taiwan, along with 12,309 controls matched for sex and age. After adjusting for confounding factors, Fine and Gray's competing risk analysis was used to compare the risk of developing dementia during the 10-year followup period. Of the enrolled patients (n=16,412), dementia developed in 303 (1.85%), including 2.56% in the study group (105 in 4103) and 1.61% (198 in 12,309) in the control group. The Fine and Gray's survival analysis revealed that the patients with charcoal-burning suicide attempts were likely to develop dementia, with a crude HR of 5.170 (95% CI 4.022 to 6.644, p<0.001). After adjusting for age, sex, comorbidity, geographic area and urbanization level of residence, and monthly insured premium, the adjusted HR was 4.220 (95% CI 3.188 to 5.586, p<0.001). Suicide attempts were associated with an increased risk of degenerative dementia in this study. Patients with charcoal-burning suicide attempts had a fourfold risk of dementia than the control group.

INTRODUCTION

Charcoal-burning suicides became an epidemic in Hong Kong,¹ Taiwan,¹⁻⁴ China,⁵⁻⁷ Korea,⁸ Japan,⁹ Singapore,¹⁰ and some Western countries such as the UK¹¹ and the USA¹² over the last two decades, which were precipitated by wide media reports¹³ or by internet browsing.¹⁴ Charcoal-burning survivors would suffer from delayed neurologic sequelae, with diffuse demyelination in the brain accompanied by lethargy, behavioral changes, forgetfulness, memory loss, and parkinsonian features, and additionally sometimes toxic or ischemic peripheral neuropathies,¹⁵ which could impair attempters' cognitive and motor functions.

Between 2011 and 2012, 130,000 people, or 4.97%, of those aged 65 years and over in Taiwan had dementia,¹⁶ which is a heavy burden for the patients and their caregivers, community, or society.¹⁷⁻²⁰ Injuries on the

Significance of this study

What is already known about this subject?

- Previous studies have found that charcoalburning survivors would suffer from delayed neurologic sequelae, involving diffuse demyelination in the brain accompanied by lethargy, behavioral changes, forgetfulness, memory loss, and parkinsonian features.
- The association between charcoal-burning suicide attempts and the risk of dementia has not yet been studied.

What are the new findings?

- Comparing with previous research on the association between carbon monoxide intoxication and the risk of dementia, this population-based study focused on the association between charcoal-burning suicidal attempts and the risk of dementia.
- The charcoal-burning suicide attempters were more likely to develop dementia (HR 4.22, 95% CI 3.19 to 5.59, p<0.001), when adjusting for sex, age, monthly income, urbanization level, geographic region, and comorbidities.
- Charcoal-burning suicide attempts were associated with an increased risk of degenerative dementia in this study.

How might these results change the focus of research or clinical practice?

If the association between charcoalburning suicide attempts and the risk of dementia is causal, then the results would remind clinicians who care for charcoalburning suicide survivors to provide careful monitoring of these patients' cognitive function in clinical practice.

brain such as traumatic brain injury (TBI),²¹ stroke,²² or even attention deficit hyperactivity disorder and related brain injury^{23 24} would also contribute to the development of dementia. Studies on delayed neurologic or neuropsychiatric syndrome revealed that carbon monoxide (CO) intoxication from charcoal-burning resulted in the diffuse demyelination in the brain.¹⁵ Another study found that the fronto-insular-caudate areas represented the target degenerative network in the CO intoxication.²⁵ Therefore, we hypothesize that CO intoxication in patients with suicide attempts would also be associated with dementia, and we conducted this study to clarify whether coal-burning suicide attempts would be associated with subsequent dementia.

METHODS

Data sources

The National Health Insurance (NHI) program was launched in Taiwan in 1995, and as of June 2009 it has included contracts with 97% of medical providers with approximately 23 million beneficiaries, or more than 99% of the entire population.²⁶ The National Health Insurance Research Database (NHIRD), which contains all claims data of the beneficiaries, uses the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes to record diagnoses.²⁷ All the diagnoses of dementia in Taiwan are made by board-certified psychiatrists or neurologists. All patients with suicide attempts by charcoal-burning would be attended and treated by emergency physicians, chest medicine specialists, intensive care physicians, or other medical experts, and the diagnosis would then be confirmed from their medical history and arterial blood gas tests. The NHI Administration randomly reviews the records of ambulatory care visits and inpatient claims to verify the accuracy of the diagnoses.²⁸ Several studies have demonstrated the accuracy and validity of several diagnoses in the NHIRD, including diabetes mellitus (DM),^{29 30} cancer,³¹⁻³³ myocardial infarction,^{29 34 35} central nervous system diseases such as Tourette syndrome,³⁶ stroke,^{29 37-40} outcomes,³³ mortality,^{29 41} or comorbidity.^{33 41} In a wide spectrum of conditions, some studies also demonstrated concordance between Taiwan's National Health Survey and the NHIRD on a variety of diagnoses,⁴² medication use,⁴² and health system utilizations.^{42,43} In this study, we used data from the Longitudinal Health Insurance Database (2000-2010), a subset of the NHIRD, to investigate the association between charcoal-burning suicide attempts and dementia over a 10-year period.

Study design

This study has a population-based, matched-cohort design. Patients with newly diagnosed charcoal-burning suicide attempts were selected from the hospitalization data set from January 1, 2000 to December 31, 2010, according to the diagnosis of the charcoal-burning suicide attempts (ICD-9-CM code: E952). Patients before 2000 were excluded. In addition, patients diagnosed with dementia before 2000 or before the first visit for charcoal-burning suicide attempts were also excluded. All patients aged <20 years were also excluded. All patients with other suicide attempts (ICD-9-CM codes: E950-E951, E953-E959) were also excluded. A total of 16,412 patients were enrolled, including 4103 subjects with charcoal-burning suicide attempts and 12,309 randomly selected sex-matched, age-matched, and index year-matched controls without charcoal-burning suicide attempts in a ratio of 1:3, with a statistical power of up to 0.875, similar to the design of our previous studies (online supplementary

figure 1).^{23 44} Age was grouped into 20–29, 30–39, 40–49, 50–59, 60–69, and \geq 70 years.

Covariates

The covariates included geographic area of residence (north, center, south, west, and east of Taiwan), urbanization level of residence (levels 1–4) and monthly income (in New Taiwan Dollars (NT\$): <18,000, 18,000–34,999, \geq 35,000).⁸ Other covariates such as complications from acute respiratory failure, rhabdomyolysis, acidosis, encephalopathy, procedures of hyperbaric oxygenation (HBO) therapy, and mechanical ventilations were also recorded.

Comorbidity

In this study, the comorbidity was used with reference to previous cohort studies on the risk factor of dementia.4445 In these two previous studies, the comorbidity was according to the RxDx-Dementia Risk Index, a useful tool to identify the risk of dementia, which has a c-statistics value of 0.806 (95% CI 0.799 to 0.812).45 Therefore, the baseline comorbidities (in ICD-9-CM codes) included DM (250), hypertension (401.1, 401.9, 402.10, 402.90, 404.10, 404.90, 405.1, 405.9), hyperlipidemia (272.x), coronary artery disease (411, 413, 414), myocardial infarction (410, 412), peripheral vascular disease (444-449), heart failure (428), obesity (278), chronic kidney disease (580, 581-589, 753, 403, 404, 250.4, 274.1, 440.1, 442.1, 447.3, 572.4, 642.1, 646.2), cerebrovascular disease (433, 434, 436), TBI (800-804, 850-854, 905.0, 950.1, 950.3, 907.0, 959.01, 959.9, 310.2, V15.52), primary cancer (140-239, with the exceptions of 190-199 and 210-229), metastatic tumor (190-199), chronic pulmonary diseases (490-496), rheumatologic disease (725-729), peptic ulcer disease (533), hemiplegia or paraplegia (342, 344), liver disease (571), AIDS (042), epilepsy (345), tuberculosis (010–018), Parkinson's disease (332), cardiac atherosclerotic cardiovascular disease (440, 441, 442, 443), glaucoma (365), cystic fibrosis (277.0x), transplantation (V42), thyroid disorder (240-246), gout (274), Crohn's disease and ulcerative colitis (555, 556), pain (338), pain and inflammations (710-719), depression (296.2, 296.3, 296.82, 300.4, 311), bipolar disorders (296.4x, 296.5x, 296.6x, 296.89), anxiety disorders (300.00, 300.01, 300.02), and psychotic illness (295. xx, 298.x).

Main outcome measures

All of the study subjects were followed from the index date until the onset of dementia (ICD-9-CM codes: 290.0, 290.10, 290.11, 290.12, 290.13, 290.20, 290.21, 290.3, 290.41, 290.42, 290.43, 290.8, 290.9, and 331.0), with-drawal from the NHI program, or at the end of year 2010. Dementia was divided into three subgroups: Alzheimer-type dementia (331.0), vascular dementia (ICD-9-CM codes: 290.4x), and other degenerative dementia (ICD-9-CM codes: 290.4x), and other degenerative dementia (ICD-9-CM codes: 290.4x), with the exception of 290.4x). As mentioned above, all the diagnoses of dementia in Taiwan are made by board-certified psychiatrists or neurologists, and for the types of dementia the NHI Administration also randomly reviews the records of ambulatory care visits and inpatient claims to verify the accuracy of the diagnoses.²⁸

All statistical analyses were performed using SPSS for Windows, V.22.0. χ^2 and t-tests were used to evaluate the distribution of categorical and continuous variables, respectively, with the Fisher's exact examination. Fine and Gray's competing risk analysis was used to determine the risk of dementia, since death can act as a competing risk factor,^{44 46 47} and the results were presented as HR with 95% CI. Differences in the risk of dementia between the study and control groups were estimated using the Kaplan-Meier method with the log-rank test. A two-tailed p value <0.05 was considered to indicate statistical significance.

RESULTS

Sample characteristics

Table 1 shows the proportion of outcomes (with or without suicide) among exposure groups of sex, age, comorbidities, urbanization, and area of residence, and the income of the charcoal-burning cohort and controls. For most of the exposure groups with comorbidities, the proportions of outcome with charcoal-burning suicides were lower than the proportions of outcome without suicide, except DM. For the exposure groups with HBO therapy, the proportions of outcome with charcoal-burning suicide were higher than the proportions of outcome without suicide. With regard to the exposure groups in different urbanization levels and location of residence, the patients in urbanization level 2, middle, southern and eastern Taiwan showed higher proportions of outcome with charcoal-burning suicide. The exposure group with monthly insured premium lower than NT\$18,000 revealed higher proportion of outcome with suicide.

Kaplan-Meier model for the cumulative risk of dementia

At the end of follow-up, 303 patients out of a total of 16,412 enrolled subjects (1.85%) had developed dementia, including 2.6% in the study group (105 in 4103) and 1.6% (198 in 12,309) in the control group, and the Kaplan-Meier analysis for the cumulative incidence of dementia in the study and control groups is shown in figure 1 (log-rank test <0.001). In addition, the percentage of use of HBO therapy in the charcoal-burning cohort was 19.0% (779 in 4103). Table 2 shows the results of Fine and Gray's competing risk analysis of the factors associated with the risk of developing dementia. The crude HR was 5.17 (95% CI 4.00 to 6.64, p<0.001). After adjusting for age, sex, comorbidities, geographic area of residence, urbanization level of residence, and monthly income, the adjusted HR was 4.22 (95% CI 3.19 to 5.87, p<0.001). In addition, male subjects were at a 1.57-fold risk than female subjects (p < 0.001). With regard to age, those who were aged 60–69 and \geq 70 years old had 1.66-fold and 2.88-fold risk in comparison with the reference group, that is, those aged 20-29. In addition, a 1-year increase in age increases the additional risk of dementia by 1.03%. Similarly, the charcoal-burning cohort with complications such as acute respiratory failure and encephalopathy was associated with higher risk of developing dementia than those without these complications. The adjusted HR was 2.51 (95% CI 1.20 to 3.68, p<0.001) and 2.99 (95% CI 1.30 to 7.76, p<0.001) in the charcoal-burning cohort who had received HBO

therapy for 1–3 times and >3 times, respectively, in contrast to the control group.

Sensitivity analysis for the risk of dementia

We have conducted two types of sensitivity analysis to evaluate the risk of dementia. First, we excluded patients diagnosed with dementia within the first 2 years after the charcoal-burning suicide attempts, and the adjusted HR was 3.22 (95% CI 1.96 to 5.29, p < 0.001) for patients with charcoal-burning suicide attempts (table 3). Second, we analyzed the risk of patients who attempted suicide by other methods, and the results showed that suicide attempts by solid or liquid ingestions, gases in domestic use, hanging, drowning, cutting or piercing implements, and jumping from building were not associated with the risk of dementia. However, the subgroup of other methods of suicides (ICD-9-CM code E958) has elevated risk of dementia (adjusted HR=3.30, 95% CI 2.44 to 6.04, p<0.001) (table 4).

Types of dementia in patients after charcoal-burning suicide attempts

With regard to the types of dementia, the study group was associated with a 4.28-fold (p<0.001) risk in developing degenerative dementia than the control group of non-attempters, and most were of the degenerative types, but not significantly associated with Alzheimer dementia (AD) or vascular dementia (VaD) (table 5).

DISCUSSION

Association between charcoal-burning suicide attempts and the risk of dementia

In this study, we found that in the 10-year follow-up of the subject group and the control group, the charcoal suicide attempts were associated with a higher risk of developing dementia. The log-rank of the Fine and Gray's competing risks regression model was significant (p < 0.001). The crude HR of the subject group was 5.17 (95% CI 4.02 to 6.64, p<0.001), and the adjusted HR was 4.22 (95% CI 3.19 to 5.87, p<0.001). We have also conducted two sensitivity analyses to evaluate the influences from protopathic bias. First, even though the patients with the diagnosis of dementia within the first 2 years were excluded, the charcoal-burning suicide attempts were still associated with increased risk of dementia. Second, suicide attempts by solid or liquid ingestions, gases in domestic use, hanging, drowning, cutting or piercing implements, and jumping from building were not associated with the risk of dementia. H owever, the subgroup of other methods of suicides (ICD-9-CM code E958) was associated with a 3.3-fold risk of dementia (p < 0.001), and we speculate that some patients with charcoal-burning suicide attempts might have been classified into this category. Comparing with previous research about the association between CO intoxication and the risk of dementia,48 49 this study focused on charcoal-burning suicide attempts and the risk of dementia. To our best knowledge, this is the first nationwide, population-based cohort study that focused on the association between charcoal-burning suicide attempts and the risk of dementia.

Table 1 Characteristics of the study population at baseline

Charcoal-burning suid	cide Total	With suicide		Without suicide		
Variables	Ν	n	%	n	%	P values
Total	16,412	4103	25.0	12,309	75.0	
Sex						
Male	9120	2280	25.0	6840	75.0	0.999
Female	7292	1823	25.0	5469	75.0	0.999
Age (years)	38.43±12.75	38.00±11.92		38.58±13.02		0.077
Age groups (years)						
20–29	4812	1203	25.0	3609	75.0	0.999
30–39	5288	1322	25.0	3966	75.0	0.999
40–49	3812	953	25.0	2859	75.0	0.999
50–59	1764	441	25.0	1323	75.0	0.999
60–69	456	114	25.0	342	75.0	0.999
≥70	280	70	25.0	210	75.0	0.999
Comorbidity						
Diabetes mellitus						
Without	15,576	3914	25.1	11,662	74.9	0.064
With	836	189	22.6	647	77.4	0.053
Hypertension						
Without	15,571	3923	25.2	11,648	74.8	0.008
With	841	180	21.4	661	78.6	0.006
Hyperlipidemia						
Without	16,175	4075	25.2	12,100	74.8	<0.001
With	237	28	11.8	209	88.2	<0.001
Ischemic heart disease						
Without	15,972	4044	25.3	11,928	74.7	<0.001
With	440	59	13.4	381	86.6	<0.001
Myocardial infarction						
Without	16,320	4089	25.1	12,231	74.9	0.026
With	92	14	15.2	78	84.8	0.014
Peripheral vascular dise			1512	,,,	0110	01011
Without	16,395	4102	25.0	12,293	75.0	0.050
With	17	1	5.9	16	94.1	< 0.001
Heart failure	17	I	5.5	10	54.1	<0.001
Without	16,328	4092	25.1	12,236	74.9	0.013
With	84	11	13.1	73	86.9	0.005
	04	11	15.1	75	00.9	0.000
Obesity	16 407	4101	25.0	12 206	75.0	0 1 2 2
Without	16,407	4101	25.0	12,306	75.0	0.132
With	5	2	40.0	3	60.0	0.486
Chronic kidney disease	10.000	2000	247	13.073	75.3	.0.004
Without	16,033	3960	24.7	12,073	75.3	<0.001
With	379	143	37.7	236	62.3	<0.001
Stroke	46.277	4002	25.4	42.424	74.0	
Without	16,277	4083	25.1	12,194	74.9	0.008
With	135	20	14.8	115	85.2	0.004
Traumatic brain injury						
Without	15,099	3853	25.5	11,246	74.5	<0.001
With	1313	250	19.0	1063	81.0	<0.001
Primary cancer						
Without	15,832	4042	25.5	11,790	74.5	<0.001
With	580	61	10.5	519	89.5	<0.001
Metastatic tumor						
Without	16,250	4089	25.2	12,161	74.9	<0.001
With	162	14	8.6	148	91.4	<0.001
Chronic obstructive pul	monary disease					
Without	16,096	4053	25.2	12,043	74.8	<0.001
With	316	50	15.8	266	84.2	<0.001
Rheumatoid arthritis						
Without	15,894	3729	23.5	12,165	76.5	<0.001

Table 1 Continued

Charcoal-burning suicide	Total	With suicide		Without suicide		
Variables	Ν	n	%	n	%	P values
With	518	374	72.2	144	27.8	<0.001
Peptic ulcer disease						
Without	16,326	4095	25.1	12,231	74.9	0.001
With	86	8	9.3	78	90.7	<0.001
Hemiplegia or paraplegia						
Without	16,334	4090	25.0	12,244	75.0	0.014
With	78	13	16.7	65	83.3	<0.001
Liver disease						
Without	15,740	4028	25.6	11,712	74.4	<0.001
With	672	75	11.2	597	88.8	<0.001
AIDS						
Without	16,396	4090	25.0	12,306	75.1	< 0.001
With	16	13	81.3	3	18.8	<0.001
Epilepsy						
Without	16,376	4091	25.0	12,285	75.0	0.144
With	36	12	33.3	24	66.7	0.265
Tuberculosis			55.5	- 1		0.205
Without	16,331	4096	25.1	12,235	74.9	<0.001
With	81	4050	8.61	74	91.4	0.001
Parkinson's disease	01	1	0.01	/4	51.4	0.001
Without	16,376	4081	24.91	12,295	75.1	<0.001
With	36	22	61.11	12,295	38.9	<0.001
Atherosclerotic cardiovascul		22	01.11	14	30.9	<0.001
		4103	25.0	10 304	75.0	0.010
Without	16,397		25.0	12,294		0.013
With	15	0	0.00	15	100.0	<0.001
Glaucoma	46.204	44.00	25.0	42.202	75.0	0.004
Without	16,394	4102	25.0	12,292	75.0	<0.001
With	18	1	5.6	17	94.4	<0.001
Cystic fibrosis						
Without	16,412	4103	25.0	12,309	75.0	0.999
With	0	0	-	0	-	
Transplantation						
Without	16,402	4103	25.0	12,299	75.0	0.058
With	10	0	0	10	100	<0.001
Thyroid disorder						
Without	16,303	4090	25.1	12,213	74.9	0.002
With	109	13	11.9	96	88.1	0.001
Gout						
Without	16,251	4080	25.1	12,171	74.9	0.003
With	161	23	14.3	138	85.71	<0.001
Crohn's disease and ulcerativ	ve colitis					
Without	16,402	4103	25.0	12,299	75.0	0.056
With	10	0	0	10	100	<0.001
Pain						
Without	16,412	4103	25.0	12,309	75.0	0.999
With	0	0	-	0	-	-
Pain and inflammations						
Without	16,159	4086	25.3	12,073	74.7	< 0.001
With	253	17	6.7	236	93.3	<0.001
Depression						
Without	14,934	2676	17.9	12,258	82.1	<0.001
With	1478	1427	96.6	51	3.5	<0.001
Bipolar disorders		1767	50.0	51	5.5	20.001
Without	16,355	4074	24.9	12,281	75.1	<0.001
With	57	29	50.9	28	49.1	<0.001
Anxiety disorders	10	23	50.5	20	43.1	<0.001
Without	16,349	4068	24.9	12,281	75.1	< 0.001

Table 1 Continued

Charcoal-burning suicide	Total	With suicide		Without suicide		
Variables	N	n	%	n	%	P values
With	63	35	55.6	28	44.4	<0.001
Psychotic illness						
Without	15,997	4016	25.1	11,981	74.9	0.037
With	415	87	21.0	328	79.0	0.028
Hyperbaric oxygenation thera	ру					
Without	15,631	3324	21.3	12,307	78.7	<0.001
With	781	779	99.7	2	0.3	<0.001
Urbanization level						
1 (highest)	5247	1038	19.8	4209	80.2	<0.001
2	7577	2408	31.8	5169	68.2	0.042
3	1391	269	19.3	1122	80.7	<0.001
4 (lowest)	2197	388	17.7	1809	82.3	<0.001
Location						
Northern Taiwan	6219	1308	21.07	4911	79.0	<0.001
Middle Taiwan	5112	1496	29.3	3616	70.7	<0.001
Southern Taiwan	4183	1076	25.7	3107	74.3	<0.001
Eastern Taiwan	846	221	26.1	625	73.9	<0.001
Outlets islands	52	2	3.9	50	96.2	<0.001
Insured premium (New Taiwa	n dollars)					
<18,000	16,033	4042	25.2	11,991	74.8	0.007
18,000–34,999	271	54	19.9	217	80.1	0.001
≥35,000	108	7	6.5	101	93.5	<0.001

P values (categorical variable: proportion test; continuous variable: t-test).

Types of dementia in this study

In this sample, 303 patients out of a total of 16,412 enrolled subjects (1.9%) had developed dementia, including 2.6% in the study group (105 in 4103) and 1.6% (198 in 12,309) in the control group, and the percentage was close to the prevalence of 2%–5% for the population aged ≥ 65 in community studies.^{50 51} In Taiwan, several community studies revealed that AD was the most common type of dementia (40%–60% of all dementias), followed by VaD (20%–30% of all dementias), and mixed or other dementias (7%–15%).^{50 52 53} This finding reflects the fact that patients with dementia




Figure 1 Kaplan-Meier for cumulative risk of dementia among aged 20 and over stratified by charcoal-burning suicide with log-rank test.

tended to be younger in the study subject group: 95 of the 105 (90.47%) patients who developed degenerative dementia were <60 years old and related to the sequelae of charcoal-burning. Nevertheless, the charcoal-burning cohort aged >60 were associated with an increased risk of dementia: adjusted HR 1.66 (95% CI 1.01 to 2.68, p=0.045) in the charcoal-burning cohort aged 60–69, and 2.88 (95% CI 1.73 to 4.70, p<0.001) in comparison with the control group.

Possible mechanisms for the increased risk of dementia in charcoal-burning suicide attempters

Studies on delayed neurologic or neuropsychiatric syndrome revealed that CO intoxication from charcoal-burning resulted in the diffuse demyelination in the brain.¹⁵ One study found that the fronto-insular-caudate areas represented the target degenerative network in CO intoxication.²⁵ The decrease in the gray matter volume in the bilateral basal ganglia, left postcentral gyrus, and left hippocampus is also correlated with the decreased perceptual organization and processing speed function in these patients.54 55 Therefore, these wide varieties of brain damage could well play an important role in the development of dementia. In our study, the subjects with stroke, TBI, epilepsy, PD, depression, and bipolar disorder showed a higher risk in developing dementia, and these findings hint that the neurologic or psychiatric disorders were at a higher vulnerability to develop a CO-induced brain damage.

HBO therapy and dementia after charcoal-burning suicide attempts

In our study, the usage of HBO therapy in the charcoal-burning cohort was 19.0% (779 in 4103), which was compatible with another study in Taiwan in which

	No competing	No competing risk in the model Competing risk in the model						
Variables	Adjusted HR	95% CI Lower limit	95% CI Upper limit	P values	Adjusted HR	95% Cl Lower limit	95% CI Upper limit	P values
Charcoal-burning s								
Without	Reference				Reference			
With	4.01	3.03	5.30	<0.001	4.22	3.19	5.59	<0.001
Sex	1.01	5.05	5.50	(0.001	1.22	5.15	5.55	0.001
Male	1.59	1.25	2.04	<0.001	1.57	1.22	2.00	<0.001
Female	Reference	1.25	2.01	(0.001	Reference	1.22	2.00	0.001
Age groups (years)					herenee			
20–29	Reference				Reference			
30-39	0.84	0.55	1.26	0.395	0.89	0.58	1.35	0.570
40-49	0.79	0.55	1.22	0.290	0.79	0.50	1.23	0.298
50-59	0.80	0.51	1.27	0.349	0.90	0.56	1.44	0.646
60-69	1.12	0.71	1.78	0.618	1.65	1.01	2.70	0.040
≥70	2.12	1.34	3.36	0.001	2.85	1.73	4.69	< 0.001
Comorbidity	2.12	1.54	5.50	0.001	2.05	1.75	UJ	<0.001
Diabetes mellitus								
Without	Reference				Reference			
With	1.09	0.76	1.57	0.638	0.94	0.65	1.35	0.732
	1.09	0.70	1.57	0.058	0.54	0.05	1.55	0.732
Hypertension Without	Reference				Reference			
With	1.19	0.84	1.70	0.328	0.96	0.68	1.37	0.834
	1.19	0.04	1.70	0.526	0.90	0.00	1.57	0.054
Hyperlipidemia	Deference				Deference			
Without	Reference	0.16	1.10	0.101	Reference	0.15	1 1 2	0.000
With	0.43	0.16	1.18	0.101	0.41	0.15	1.12	0.082
Ischemic heart dise					P (
Without	Reference			0.000	Reference			
With	0.65	0.31	1.34	0.239	0.59	0.24	1.21	0.147
Myocardial infarcti					D (
Without	Reference				Reference			
With	0.45	0.06	3.24	0.426	0.43	0.06	3.14	0.408
Peripheral vascular					- /			
Without	Reference				Reference			
With	0.91	0.13	6.59	0.923	0.83	0.11	6.06	0.856
Heart failure								
Without	Reference				Reference			
With	0.53	0.13	2.14	0.369	0.46	0.11	1.86	0.272
Obesity								
Without	Reference				Reference			
With	0.00	-	-	0.984	0.00	-	-	0.984
Chronic kidney dis								
Without	Reference				Reference			
With	1.19	0.65	2.21	0.574	1.11	0.60	2.08	0.736
Stroke								
Without	Reference				Reference			
With	3.86	2.29	6.49	<0.001	3.32	1.98	5.58	<0.001
Fraumatic brain inj	ury							
Without	Reference				Reference			
With	1.44	0.99	2.08	0.055	1.45	1.00	2.10	0.050
Primary cancer								
Without	Reference				Reference			
With	0.18	0.07	0.48	0.001	0.16	0.06	0.44	<0.001
Metastatic tumor								
Without	Reference				Reference			
With	1.52	0.51	4.53	0.449	1.51	0.51	4.46	0.457
	e pulmonary disease							

Name Name		No competing	risk in the model			Competing risk	in the model						
Web Resunational attribute1,320,722,290,3081,000,571,750,989Resunational attributeReferenceReference0,4291,740,440MythoutReferenceReference0,4290,710,440MythoutReferenceReference0,710,4200,70<	Variables	Adjusted HR			P values	Adjusted HR			P values				
Withou defenseVersion of the defenseWithou 0.700.291.700.4250.710.291.700.440Peptic detensesVersion of the defenseVersion of the defense <t< td=""><td>Without</td><td>Reference</td><td></td><td></td><td></td><td>Reference</td><td></td><td></td><td></td></t<>	Without	Reference				Reference							
Whine Whine Whine Whine Representation Whine Representation Rep	With	1.33	0.77	2.29	0.308	1.00	0.57	1.75	0.998				
Which QringReferenceReferenceSelectionWithou Reprint outReference0.1200.4290.1700.4290.1710.440Withou ReferenceReferenceReference0.1720.1720.1720.1720.172Withou ReferenceReferenceReference0.1720.1530.1720.1530.1720.1530.172Withou ReferenceReferenceReference0.1720.1530.1720.1530.1720.164Withou ReferenceReferenceReference0.1720.1720.1630.1720.164Withou ReferenceReference0.1720.1610.180.2920.161Withou ReferenceReference0.1640.100.140.140.100.140.161 </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>													
Paper and the series of the s						Reference							
Paper and the series of the s	With	0.70	0.29	1.70	0.425	0.71	0.29	1.71	0.440				
Without With With 2,000.884.540.0981.780.784.01 0.172Without Beference With 1.320.533.030.5511.770.533.420.502Without Beference With 1.320.533.030.5511.370.553.420.505User disease User diseaseReferenceReferenceNo1.530.641.810.7741.130.731.900.641AIDS With DifferenceReferenceReferenceNo0.189.380.794AIDS User diseaseReferenceReferenceNo0.189.380.794AIDS User disease1.010.147.230.9961.300.189.380.794AIDS User diseaseReferenceReferenceNo0.0010.189.380.794AIDS User disease1.630.525.140.4061.550.425.82<0.001	Peptic ulcer disease	e											
With templagia pramupa Hemplagia pramupa<	•					Reference							
Wrhout Wrhout 1,320,533,030,511,370,553,420,505Wrhout Ner diseaseReferenceReferenceNo0,640,000,640,640,000,010,840,260,0010,140,020,0011,630,610,0010,140,020,011,331,666,670,0010,140,000,011,331,666,670,0010,140,000,010,140,000,010,150,160,010,160,010,160,010,160,010,160,010,160,010,160,010,160,010,160,010,160,010,160,010,160,010,160,010,160,010,160,010,160,010,160,010,160,010,160,160,160,160,160,160,160,160,160,160,160,160,160,16			0.88	4.54	0.098		0.78	4.05	0.172				
Without Without 1,320,533,030,511,370,553,420,505Without With 1,080,641,310,771,370,553,420,505Without MineReferenceReferenceReference0,641,300,640,040,640,640,000,640,000,640,000,040,050,050,050,050,050,050,050,050,050,050,050,050,061,050,060,010,060,010	Hemiplegia or para	aplegia											
Network with the second secon						Reference							
Network series with the series of the serie			0.53	3.03	0.551		0.55	3.42	0.505				
Without Without NoReferenceReferenceReferenceWithout NoReferenceReferenceReferenceReferenceWithout NoReferenceReferenceReferenceReferenceWithout NoReferenceReferenceReferenceReferenceWithout NoReferenceReferenceReferenceReferenceWithout NoReferenceReferenceReferenceReferenceWithout NoReferenceReferenceReferenceReferenceWithout NoReferenceReferenceReferenceReferenceWithout NoReferenceReferenceReferenceReferenceWithout ReferenceReferenceReferenceReferenceReferenceWithout NoReferenceReferenceReferenceReferenceReferenceWithout NoReferenceReferenceReferenceReferenceReferenceWithout NoReferenceReferenceReferenceReferenceReferenceWithout NoReferenceReferenceReferenceReferenceReferenceWithout NoReferenceReferenceReferenceReferenceReferenceReferenceWithout NoReferenceReferenceReferenceReferenceReferenceReferenceReferenceWithout NoReferenceReferenceReferenceReferenceReferenceReferenceReferenceReferenceReferenceReference <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>													
Within ID80.641.810.7741.130.671.900.641ADSWithin ID100.147.230.9961.300.189.380.794Difley:Within ID100.147.230.9961.300.189.380.794Difley:Within ID102.237.52<0.001		Reference				Reference							
AIDSWitho With L00.100.147.230.9961.300.189.380.794EplepsyReferenceWithout L1020.120.9161.300.189.380.794Without L1020.120.9161.300.189.380.794Without L1020.120.9161.450.4550.490.180.000.00Uthout L1020.550.490.4920.4550.494.920.455Parkinovi SilesseReferenceWithout MereneReferenceReferenceWithout MereneReferenceReferenceWithout MereneReferenceReferenceWithout Mithout ReferenceReferenceReferenceWithout Mithout ReferenceReferenceReferenceWithout Mithout ReferenceReferenceReferenceWithout Mithout ReferenceReferenceReferenceWithout Mithout ReferenceReferenceReferenceWithout Mithout ReferenceReferenceReferenceWithout Mithout ReferenceReferenceReferenceWithout Mithout ReferenceReferenceReferenceWithout Mithout ReferenceReferenceReferenceWithout Mithout ReferenceReferenceReference<		1.08	0.64	1.81	0.774		0.67	1.90	0.641				
Without Without WithoutReference													
With tpilepry1.010.147.230.9961.300.189.380.794Kithout to ReferenceReferenceReference </td <td></td> <td>Reference</td> <td></td> <td></td> <td></td> <td>Reference</td> <td></td> <td></td> <td></td>		Reference				Reference							
PerformeReferenceReferenceset and the set of the se			0.14	7.23	0.996		0.18	9.38	0 794				
Without With UtervaloisReferenceReferenceWithout MetervaloisReferenceReferenceReferenceWithout MithoutReferenceReferenceReferenceWithout Methout ReferenceReferenceReferenceReferenceWithout Methout ReferenceReferenceReferenceReferenceWithout Methout ReferenceReferenceReferenceReferenceWithout Methout ReferenceReferenceReferenceReferenceWithout Methout ReferenceReferenceReferenceReferenceWithout Methout ReferenceReferenceReferenceReferenceWithout Methout ReferenceReferenceReferenceReferenceWithout Methout ReferenceReferenceReferenceReferenceWithout Mohout ReferenceReferenceReferenceReferenceWithout Mohout ReferenceReferenceReferenceReferenceWithout Mohout ReferenceReferenceReferenceReferenceWithout Mohout ReferenceReferenceReferenceReferenceWithout Mohout ReferenceReferenceReferenceReferenceReferenceWithout Mohout ReferenceReferenceReferenceReferenceReferenceWithout Mohout ReferenceReferenceReferenceReferenceReferenceWithout Mohout ReferenceReferenceReferenceReferenceReferenceWithout Moh		1.01	0.14	1.25	0.550	1.50	0.10	5.50	0.754				
With therease4.102.237.52<.0.014.502.458.28<.0.001TubercuisisReferenceReferenceReferenceControlCont		Reference				Reference							
ReferenceWithouReferenceReferenceWith1.630.525.140.4061.550.494.920.455Parkinson's diseaseReferenceReference0.0013.331.666.670.001MithoutReferenceReferenceReference0.0013.331.666.670.001MithoutReferenceReferenceReference0.0010.0110.0010.0110.0010.0110.01010.0110.01010.01010.0110.01010.0110.01010.0110.01010.0110.01010.0110.01010.0110.01010.0110.01010.0110.01010.0110.01010.0110.0110.01010.0110.0110.0110.0110.011			2.22	7.52	<0.001		2.45	0.70	<0.001				
WithoutReferenceReferenceWith1.630.525.140.4061.550.494.920.455Parkinson's diseaseReferenceReference0.0013.331.666.670.001Atherosoclerotic catiour-scular diseaseReferenceReference0.00170.0780.00-0.9780.001-0.9780.001-0.9780.001-0.9780.001-0.9780.001-0.9780.001-0.9780.001-0.9780.001-0.9780.001-0.9780.001-0.9780.001-0.9780.001-0.9780.001-0.9780.001-0.9780.001-0.9780.001-0.9780.001-0.9780.001-0.9780.001 <td></td> <td>4.10</td> <td>2.23</td> <td>7.52</td> <td><0.001</td> <td>4.50</td> <td>2.45</td> <td>0.20</td> <td><0.001</td>		4.10	2.23	7.52	<0.001	4.50	2.45	0.20	<0.001				
With 1.63 0.52 5.14 0.406 1.55 0.49 4.92 0.455 Parkinsor's disease Without Reference Reference 0.001 3.06 6.67 0.001 Without A deference Reference Reference 0.001 1.66 6.67 0.001 Atherosclerotic cardiovascular disease Reference Reference 0.001 - - 0.978 0.000 - - 0.978 0.001 - - 0.978 0.43 22.08 0.264 0.264 Glaucoma Reference Reference Reference - - 0.978 0.43 22.08 0.264 0.274 0.264 0.264 0.274 0.264 0.274 0.264 0.274 0.274 0.274 0.274 0.274 0.274 0.274 0.274 0.274 <t< td=""><td></td><td>Deference</td><td></td><td></td><td></td><td>Deference</td><td></td><td></td><td></td></t<>		Deference				Deference							
Parkinson's diseaseWithoutReferenceReferenceWith4.612.349.81<0.001			0.50	F 14	0.400		0.40	4.02	0.455				
WithoutReferenceReferenceWith4.612.349.81<0.001			0.52	5.14	0.406	1.55	0.49	4.92	0.455				
With4.612.349.81<0.0013.331.666.670.001Atherosclerotic cardiovascular <td< td=""><td></td><td></td><td></td><td></td><td></td><td>D (</td><td></td><td></td><td></td></td<>						D (
diseaseReferenceWithoutReference-0.9780.000.978GlaucomaReferenceReferenceReference0.010.0322.080.264VithoutReferenceReferenceReference0.010.020.264VithoutReferenceReference0.020.020.264VithoutReferenceReference0.010.02WithoutReferenceWithoutReferenceWithoutReference0.9740.000.974UrithoutReference0.9740.0740.000.974WithoutReference0.9740.0740.000.974WithoutReference0.9740.9740.9740.9740.9740.974WithoutReference0.9740			2.24	0.01	0.004		4.66	6.67	0.004				
disease in the ference of the feren			2.34	9.81	<0.001	3.33	1.00	6.67	0.001				
With Glaucoma0.000.9780.000.978GlaucomaWithoutReferenceWithout0.5528.320.1713.080.4322.080.264Cystic fibrosisWithoutReference <td>disease</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	disease												
Glaucoma Reference Reference With 0 3.95 0.55 28.32 0.171 3.08 0.43 22.08 0.264 Cystic fibrosis 7 0.55 28.32 0.171 3.08 0.43 22.08 0.264 Cystic fibrosis Reference 0.264 0.264 0.264 0.264 0.264 0.264 0.264 0.264 0.264 0.264 0.264 0.264 0.264 0.264 0.264 0.264 0.264 0.264 0.76 7 0.74 0.974 0.70 0.704 0.702 0.764 0.19 3.10 0.702 0.702 0.764 0.19 3.10 0.702					0.070				0.070				
Without Reference Reference Without 3.95 0.55 28.32 0.171 3.08 0.43 22.08 0.264 Cystic fibrosis Vithout Reference Reference Image: Constraint of the second of		0.00	-	-	0.978	0.00	-	-	0.978				
With 3.95 0.55 28.32 0.171 3.08 0.43 22.08 0.264 Cystic fibrosis		5.6				P (
Reference Without Reference Reference Without Reference Reference Reference Without Reference Reference Reference Without 0.00 - - 0.974 0.00 - - - - Without Reference Refer													
Without Reference Reference Without - 0.974 0.00 - - - 0.974 0.00 - - - 0.974 0.974 0.974 0.00 - - 0.974 0.974 0.974 0.974 0.974 0.974 0.974 0.00 - - 0.974 0.974 0.974 0.974 0.974 0.974 0.9702 0.974 0.673 0.76 0.19 3.10 0.702 0.243 0.243 0.578 0.66 0.21 2.07 0.474 <t< td=""><td></td><td>3.95</td><td>0.55</td><td>28.32</td><td>0.171</td><td>3.08</td><td>0.43</td><td>22.08</td><td>0.264</td></t<>		3.95	0.55	28.32	0.171	3.08	0.43	22.08	0.264				
WithWithoutReferenceIII <td< td=""><td>-</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>	-												
Transplantation Reference Reference Without 0.00 - - 0.974 0.00 - - 0.974 Without 0.00 - - 0.974 0.00 - - 0.974 Thyroid disorder - - 0.974 0.00 - - 0.974 Without Reference - Reference - - 0.974 0.974 0.974 0.974 0.974 0.974 0.974 0.974 0.974 0.974 0.974 0.974 0.974 0.974 0.974 0.970 0.974 0.970 0.974 0.970 0.970 0.974 0.970 0.974 0.970 0.974 0.970 0.974 0.974 0.974 0.974 0.970 0.974 <td></td> <td>Reference</td> <td></td> <td></td> <td></td> <td>Keterence</td> <td></td> <td></td> <td></td>		Reference				Keterence							
Without Reference Without 0.00 $ -$ 0.974 With 0.00 $ -$ 0.974 Tyroid disorder Reference Without Reference Score Without Reference Reference Without Reference Score Without Reference <th colspan="4" score<="" td="" tho<=""><td></td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></th>	<td></td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td>					-	-	-	-	-	-	-	-
With 0.00 - - 0.974 0.00 - - 0.974 Thyroid disorder Mithout Reference Reference Reference Reference Reference No.019 3.10 0.702 Gout Nithout Reference Reference Reference No.019 3.10 0.702 Without Reference No.02 0.23 2.28 0.578 0.66 0.21 2.07 0.474 Crohn's disease and Userstrive Scover Scover Scover Scover Scover 0.45 0.43 0.45 0.43 0.45 0.43 0.45 0.43 0.45 0.43 0.45 0.43 0.45 0.43 0.45 0.43 0.45 0.43 0.45 0.43 0.45 0.43 0.45 0.43 0.45 0.43 0.45 0.43 0.45 0.43 0.45 0.45 0.43 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 <	-												
Thyroid disorder Reference Reference Without 0.74 0.18 3.01 0.673 0.76 0.19 3.10 0.702 Gout Vithout Reference Reference Vithout Reference 0.72 0.23 2.28 0.578 0.66 0.21 2.07 0.474 Crohn's disease and Ucrative collision Vithout Reference Reference Vithout 23.29 0.243 3.24 0.45 23.29 0.243 Without Reference Reference Reference Vithout - - - - Without Reference Reference Reference Vithout -													
Without Reference Reference With 0.74 0.18 3.01 0.673 0.76 0.19 3.10 0.702 Gout Without Reference Reference V <		0.00	-	-	0.974	0.00	-	-	0.974				
With 0.74 0.18 3.01 0.673 0.76 0.19 3.10 0.702 Gout Without Reference Reference Reference 12.07 0.474 With 0.72 0.23 2.28 0.578 0.66 0.21 2.07 0.474 Crohn's disease and ulcerative colitis V	-												
Gout Reference Reference With 0 0.72 0.23 2.28 0.578 0.66 0.21 2.07 0.474 Crohn's disease and Ucrative colitis Crohn's disease colitis													
WithoutReferenceReferenceWith0.720.232.280.5780.660.212.070.474Crobn's disease and UcrativeCrobn's disease and Ucrative		0.74	0.18	3.01	0.673	0.76	0.19	3.10	0.702				
With 0.72 0.23 2.28 0.578 0.66 0.21 2.07 0.474 Crohn's disease and ulcerative colitis V <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>													
Crohn's disease and ulcerative solutions Without Reference Reference 23.29 0.243 3.24 0.45 23.29 0.243 Without Reference Reference Colspan="5">Colspan= Solution Soluti Solution Solution Solution Solution Solution Solution													
Reference Without Reference Reference Without 3.24 0.45 23.29 0.243 Pain Reference Without Reference - <td></td> <td></td> <td>0.23</td> <td>2.28</td> <td>0.578</td> <td>0.66</td> <td>0.21</td> <td>2.07</td> <td>0.474</td>			0.23	2.28	0.578	0.66	0.21	2.07	0.474				
With 3.24 0.45 23.32 0.243 3.24 0.45 23.29 0.243 Pain Reference Reference <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>													
Pain Reference Ref	Without	Reference				Reference							
Without Reference Reference With - </td <td>With</td> <td>3.24</td> <td>0.45</td> <td>23.32</td> <td>0.243</td> <td>3.24</td> <td>0.45</td> <td>23.29</td> <td>0.243</td>	With	3.24	0.45	23.32	0.243	3.24	0.45	23.29	0.243				
With -	Pain												
Pain and inflammations Without Reference Reference	Without	Reference				Reference							
Without Reference Reference	With	-	-	-	-	-	-	-	-				
	Pain and inflamma	tions											
With 0.88 0.39 2.00 0.77 0.78 0.34 1.76 0.547	Without	Reference				Reference							
	With	0.88	0.39	2 00	0.77	0.78	0.34	1.76	0 547				
									~				

Continued

Table 2 Continued

	No competing	risk in the model			Competing risk	in the model		
Variables	Adjusted HR	95% Cl Lower limit	95% Cl Upper limit	P values	Adjusted HR	95% Cl Lower limit	95% Cl Upper limit	P values
Depression								
Without	Reference				Reference			
With	2.46	1.70	3.56	<0.001	2.49	1.72	3.61	< 0.001
Bipolar disorders								
Without	Reference				Reference			
With	2.81	1.37	5.73	0.005	2.76	1.35	5.64	0.005
Anxiety disorders								
Without	Reference				Reference			
With	0.00	-	-	0.953	0.00	-	-	0.953
Psychotic illness								
Without	Reference				Reference			
With	1.03	0.62	1.70	0.918	1.13	0.68	1.86	0.646
Hyperbaric oxygenati	on therapy							
Without	Reference				Reference			
With	2.71	1.12	6.57	0.027	2.80	1.15	6.77	0.023
Urbanization level								
1 (highest)	1.04	0.75	1.45	0.797	1.05	0.75	1.45	0.792
2	0.78	0.57	1.07	0.126	0.78	0.57	1.08	0.131
3	0.96	0.62	1.48	0.856	1.02	0.66	1.57	0.929
4 (lowest)	Reference				Reference			
Location								
Northern Taiwan	Had collinearity	with urbanization le	evel		Had collinearity	with urbanization le	evel	
Middle Taiwan	Had collinearity	with urbanization le	evel		Had collinearity	with urbanization le	evel	
Southern Taiwan	Had collinearity	with urbanization le	evel			with urbanization le		
Eastern Taiwan	Had collinearity	with urbanization le	evel		Had collinearity	with urbanization le	evel	
Outlets islands	Had collinearity	with urbanization le	evel		Had collinearity	with urbanization le	evel	
Insured premium (Ne	w Taiwan dollars)							
<18,000	Reference				Reference			
18,000–34,999	0.80	0.26	2.50	0.700	0.80	0.25	2.49	
≥35,000	0.00	-	-	0.939	0.00	-	-	

Adjusted HR, adjusted variables listed in the table.

hyperbaric oxygen therapy was only used in 18.8% of patients.¹⁴ Evidence of HBO therapy for CO intoxication from charcoal-burning is yet to be established.⁵⁶⁻⁵⁸ However, the charcoal-burning cohort who had received HBO therapy still had an increased risk of dementia in contrast to the control group, with an adjusted HR of 2.80 (95% CI 1.15 to 6.77, p=0.023), and with an adjusted HR of 2.51 (95% CI 1.20 to 3.68, p<0.001) and 2.99 (95% CI 1.60 to 7.76, p<0.001) in the charcoal-burning cohort who had received the HBO therapy for 1–3 times and >3 times, respectively, in contrast to the control group, which were lower than the overall adjusted HR of as high as 4.28. However, further studies were indicated for the association among charcoal-burning attempts, HBO therapy and the risk of dementia.

Psychiatric disorders and risk of dementia in charcoalburning suicide attempters

In the charcoal-burning cohort, the comorbidities of depression, bipolar disorders, and anxiety disorders were higher than the control groups. This observation indicates that the prevention of charcoal-burning as a suicide method in some populations is, indeed, important. Furthermore, in the charcoal-burning cohort with stroke, TBI, epilepsy, PD, depression and bipolar disorder, the risk of developing dementia was higher than those without these comorbidities. These findings revealed that the prevention of the charcoal-burning suicide in these patients could be important. Since one study showed in its preliminary results that a charcoal-restriction program reduced the method-specific and overall suicides,⁵⁹ a larger scale and longer follow-up study is needed to evaluate the results of charcoal restriction and their effects on the prevention of suicide.

Limitations

There are several limitations to this study. First, patients with dementia could be identified using the insurance claims data; however, data on severity, stage, and impact on their caregivers were not available. The types of dementia were also identified from the ICD codes in these claims data. Second, even though only newly diagnosed dementia would be included in the follow-up period, a protopathic bias, in which the initiation of an exposure occurs in response to an undiagnosed disease (outcome) under study,⁶⁰ should also be considered since some of the subjects with charcoal-burning suicide attempts. Third, in this study, we

Table 3 Factors of dementia (first a)												
		g risk in the mo			Competing ris							
Variables	Adjusted HR	95% Cl Lower limit	95% Cl Upper limit	P values	Adjusted HR	95% Cl Lower limit	95% CI Upper limit	P values				
Charcoal-burning suicide (reference: without)	3.22	1.96	5.30	<0.001	3.22	1.96	5.29	< 0.001				
Sex (reference: male)	1.70	1.18	2.45	0.005	1.72	1.19	2.49	0.004				
Age groups (years) (reference: 20–29)												
30–39	0.63	0.30	1.31	0.213	0.63	0.31	1.32	0.223				
40–49	0.47	0.22	1.01	0.054	0.48	0.22	1.02	0.058				
50–59	0.67	0.31	1.46	0.318	0.69	0.32	1.49	0.345				
60–69	1.20	0.55	2.62	0.641	1.24	0.57	2.71	0.583				
≥70	2.03	0.94	4.41	0.073	2.14	0.98	4.66	0.056				
Comorbidity (reference: without)												
Diabetes mellitus	3.22	1.96	5.30	<0.001	1.03	0.64	1.66	0.908				
Hypertension	1.70	1.18	2.45	0.005	1.02	0.64	1.63	0.931				
Hyperlipidemia					0.35	0.08	1.49	0.156				
Ischemic heart disease	0.63	0.30	1.31	0.213	0.32	0.10	1.04	0.059				
Myocardial infarction	0.47	0.22	1.01	0.054	0.83	0.11	6.07	0.852				
Peripheral vascular disease	0.68	0.31	1.46	0.318	0.00	-	-	0.975				
Heart failure	1.20	0.55	2.62	0.641	0.68	0.16	2.83	0.592				
Obesity	2.03	0.94	4.41	0.073	0.000	-	_	0.988				
Chronic kidney disease	0.92	0.39	2.14	0.841	1.03	0.44	2.42	0.947				
Stroke	4.70	2.44	9.06	< 0.001	4.71	2.44	9.10	< 0.001				
Traumatic brain injury	1.33	0.78	2.27	0.301	1.38	0.81	2.38	0.238				
Primary cancer	0.31	0.10	0.93	0.037	0.32	0.11	0.97	0.045				
Metastatic tumor	1.08	0.23	5.10	0.923	1.15	0.24	5.41	0.859				
Chronic obstructive pulmonary disease	1.45	0.23	2.72	0.254	1.50	0.24	2.83	0.206				
Rheumatoid arthritis	0.66	0.16	2.68	0.561	0.66	0.00	2.70	0.565				
Peptic ulcer disease	2.68	0.96	7.45	0.059	2.65	0.10	7.35	0.062				
•	0.00	-	-	0.039	0.00	-	-	0.002				
Hemiplegia or paraplegia Liver disease	0.98	- 0.47	2.05	0.970	1.01	- 0.48	2.12	0.970				
AIDS	0.98	-	2.05	0.937	0.00	-	-	0.973				
Epilepsy Tuberculosis	5.21	2.36 0.51	11.47	< 0.001	5.79	2.61 0.52	12.88	< 0.001				
	2.18		9.41	0.295	2.26		9.87	0.277				
Parkinson's disease	2.27	0.67	7.65	0.186	2.27	0.67	7.67	0.187				
Atherosclerotic cardiovascular disease	0.00	-	-	0.982	0.00	-	-	0.982				
Glaucoma	7.97	1.07	59.077	0.04	7.86	1.06	58.33	0.044				
Cystic fibrosis	-	-	-	-	-	-	-	-				
Transplantation	0.00	-	-	0.981	0.00	-	-	0.981				
Thyroid disorder	0.51	0.06	4.01	0.519	0.49	0.06	3.93	0.500				
Gout	1.16	0.36	3.74	0.809	1.13	0.35	3.65	0.845				
Crohn's disease and ulcerative colitis	4.81	0.65	35.67	0.125	4.67	0.63	34.67	0.132				
Pain	-	-	-	-	-	-	-	-				
Pain and inflammations	0.42	0.10	1.72	0.228	0.41	0.10	1.67	0.221				
Depression	3.61	1.95	6.67	<0.001	3.51	1.90	6.50	<0.001				
Bipolar disorders	2.32	0.72	7.52	0.160	2.27	0.70	7.35	0.172				
Anxiety disorders	0.00	-	-	0.97	0.00	-	-	0.972				
Psychotic illness	0.61	0.25	1.53	0.294	0.61	0.24	1.51	0.284				
Hyperbaric oxygenation therapy (reference: without)	0.00	-	-	0.994	0.00	-	-	0.994				
Urbanization level (reference: 4, the lowest)												
1 (highest)	1.07	0.64	1.79	0.790	1.01	0.66	1.84	0.726				
2	0.87	0.55	1.38	0.561	0.89	0.56	1.41	0.605				
3	1.07	0.59	1.94	0.823	1.09	0.60	1.98	0.777				
Insured premium (New Taiwan dollars) (referen	ce: <18,000)											
18,000–34,999	0.59	0.35	0.98	0.042	0.57	0.34	0.96	0.033				
≥35,000	0.68	0.46	1.01	0.055	0.67	0.45	0.99	0.046				

Adjusted HR, adjusted variables listed in the table.

10

		No compe	ting risk in the	model		Competing risk in the model			
Comparison cohort	Charcoal-burning suicide (reference: without)	Adjusted HR	95% Cl Lower limit	95% CI Upper limit	P values	Adjusted HR	95% Cl Lower limit	95% CI Upper limit	P values
Without charcoal-burning	AU 1		2.02	5.20	0.004		2.4.0	5.50	
suicide	All dementia	4.01	3.03	5.30	< 0.001	4.22	3.19	5.59	< 0.001
(Without ICD-9-CM E952)	AD	4.00	0.56	29.76	0.298	4.13	0.75	30.03	0.211
	VaD Others de new constitue	7.96	0.50	38.45	0.265	8.00	0.60	48.88	0.194
	Other degenerative dementia	4.16	3.00	5.49	<0.001	4.28	3.00	5.99	<0.001
Solid or liquid suicide	All dementia	1.03	0.46	1.882	0.256	1.03	0.48	2.00	0.565
(ICD-9-CM E950)	AD	1.00	0.30	1.31	0.142	1.00	0.34	1.51	0.452
	VaD	0.99	0.22	1.25	0.667	1.00	0.23	1.49	0.701
	Other degenerative dementia	1.24	0.57	1.95	0.298	1.29	0.58	2.01	0.384
Gases in domestic use	All dementia	1.00	0.56	2.99	0.725	1.02	0.60	2.13	0.765
(ICD-9-CM E951)	AD	0.89	0.25	1.79	0.668	0.91	0.34	1.86	0.604
(VaD	1.01	0.68	3.01	0.595	1.10	0.70	3.90	0.588
	Other degenerative								
	dementia	0.97	0.42	1.90	0.480	1.00	0.45	3.00	0.484
Hanging	All dementia	0.86	0.20	7.56	0.823	0.87	0.30	8.65	0.842
(ICD-9-CM E953)	AD	0.81	0.17	7.11	0.772	0.83	0.24	8.11	0.701
	VaD	0.76	0.12	6.81	0.682	0.80	0.20	7.46	0.655
	Other degenerative dementia	0.90	0.26	8.62	0.783	0.99	0.33	9.03	0.806
Drowning	All dementia	0.46	0.18	1.00	0.047	0.51	0.21	1.06	0.062
(ICD-9-CM E954)	AD	0.86	0.55	3.59	0.598	0.87	0.60	4.76	0.498
	VaD	0.73	0.43	3.10	0.892	0.76	0.55	3.89	0.797
	Other degenerative dementia	0.43	0.17	0.98	0.040	0.44	0.19	1.00	0.050
Cutting or piercing implements	All dementia	2.99	0.99	21.10	0.062	3.00	0.99	25.41	0.058
(ICD-9-CM E956)	AD	1.07	0.24	16.25	0.774	1.13	0.29	20.00	0.735
. ,	VaD	2.14	0.46	18.48	0.688	2.19	0.50	20.15	0.612
	Other degenerative								
	dementia	3.09	0.99	28.45	0.060	3.24	1.00	33.77	0.053
Jumping from building	All dementia	0.77	0.25	8.45	0.792	0.80	0.28	9.45	0.774
(ICD-9-CM E957)	AD	0.80	0.30	9.07	0.801	0.85	0.31	10.25	0.797
	VaD	0.74	0.22	8.266	0.883	0.76	0.26	9.00	0.812
	Other degenerative dementia	0.71	0.21	8.01	0.767	0.72	0.25	8.94	0.735
Other methods of suicide	All dementia	3.27	2.40	5.89	<0.001	3.30	2.44	6.04	<0.001
(ICD-9-CM E958)	AD	3.14	0.54	29.12	0.294	3.24	0.64	31.46	0.339
	VaD	7.98	0.47	38.56	0.188	8.264	0.60	43.98	0.273
	Other degenerative dementia	3.11	2.07	5.13	<0.001	3.20	2.12	5.27	<0.001

Adjusted HR, adjusted for all the variables listed in table 2.

AD, Alzheimer dementia; ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical Modification; VaD, vascular dementia.

Table 5	Factors of the subgroup of dementia at the end of follow-up usin	a Cox regression and Fine and Gray's competing risk model

Charcoal-burning suicide		No competing	g risk in the mo	odel	Competing risk in the model				
Variables		Adjusted HR	95% CI Lower limit	95% CI Upper limit	P values	Adjusted HR	95% CI Lower limit	95% Cl Upper limit	P values
Total	105	4.01	3.03	5.30	<0.001	4.22	3.19	5.59	<0.001
Alzheimer dementia	2	4.00	0.57	29.76	0.298	4.13	0.75	30.03	0.211
Vascular dementia	1	7.99	0.50	38.45	0.265	8.00	0.598	48.88	0.194
Other degenerative dementia	102	4.16	3.00	5.50	<0.001	4.28	3.002	5.99	<0.001

Adjusted HR, adjusted for all the variables listed in table 3.

Chang S-Y, et al. J Investig Med 2018;0:1-13. doi:10.1136/jim-2018-000759

Original research

identified patients with charcoal-burning suicide attempts by ICD-9-CM code, E952. Even though there are some debates on using this code for charcoal-burning suicide,^{61 62} charcoal-burning suicide deaths increased drastically from less than 2% before 1998, to 20%–30% of all suicide deaths in Hong Kong and Taiwan within the following decade,^{63 64} and several authors therefore have used E952 code as charcoal-burning suicides in their studies.¹⁶⁵ Hence, we assumed that using E952 code to identify charcoal-burning suicide attempts could be a rational choice in Taiwan, even though no previous study has examined the operating characteristics of this code for charcoal-burning suicide attempts.

CONCLUSIONS

The patients with charcoal-burning suicide attempts had a nearly fourfold risk of dementia than the control group. Therefore, further studies are needed to elucidate the underlying mechanisms. If the association reflects a causal effect, this finding would remind clinicians who oversee care for charcoal-burning suicide survivors to make careful evaluations and follow-up for cognitive and behavioral manifestations.

Author affiliations

¹Division of Pulmonary and Critical Medicine, Department of Medicine, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan

Zaraduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan

³Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan

⁴Department of Medical Research, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

⁵School of Public Health, National Defense Medical Center, Taipei, Taiwan ⁶Taiwanese Injury Prevention and Safety Promotion Association, Taipei, Taiwan ⁷Data tenant of Purchistry, Tri Service Control Hearing, School of Medicine

⁷Department of Psychiatry, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan ⁸Student Counseling Center, National Defense Medical Center, Taipei, Taiwan

⁹Department of Psychiatry, Tri-Service General Hospital, Song-Shan Branch, National Defense Medical Center, Taipei, Taiwan

¹⁰Department of Nursing, Tri-Service General Hospital, and School of Nursing, National Defense Medical Center, Taipei, Taiwan

¹¹Department of Nursing, Kang-Ning University, Taipei, Taiwan

¹²Institute of Bioinformatics and System Biology, National Chiao Tung

University, Hsin-Chu, Taiwan ¹³Hyperbaric Oxygen Therapy Center, Division of Pulmonary and Critical Care

Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

Acknowledgements The authors thank Professors Chang-Huei Tsao, Yung-Fu Wu, Fu-Huang Lin, Chin-Bin Yeh, San-Yuan Huang, and Ru-band Lu for their help in the administrative work and academic guidance in supporting the completion of this study.

Contributors S-YC and N-ST conceived of the study, participated in its design and coordination, data interpretation, performed the statistical analysis, and drafted the manuscript. W-CC, C-HC, and H-WY participated in the design of the study and data interpretation. H-AC and Y-CK participated in the design of the study and data interpretation. C-KP, C-HS, and Y-CC participated in the statistical analysis and data interpretation. S-YC wrote the paper. All authors have read and approved the final manuscript as submitted.

Funding This work was supported by Tri-Service General Hospital Research Foundation grant numbers TSGH-C105-130, TSGH-C106-002, and TSGH-C107-004. Data for this study were based on the National Health Insurance Research Database provided by the National Health Insurance Administration of the Ministry of Health and Welfare, Taiwan, and managed by the National Health Research Institutes, Taiwan. The interpretation and conclusions contained in this article do not represent those of the National Health Insurance Administration, the Ministry of Health and Welfare, or the National Health Research Institutes.

Competing interests None declared.

Patient consent Not required.

Ethics approval This study was conducted in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki). The Institutional Review Board of the Tri-Service General Hospital approved this study and waived the need for individual consents since all the identification data were encrypted in the NHIRD (IRB No 1-104-05-145).

Provenance and peer review Not commissioned; externally peer reviewed.

© American Federation for Medical Research (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

- 1 Liu KY, Beautrais A, Caine E, et al. Charcoal burning suicides in Hong Kong and urban Taiwan: an illustration of the impact of a novel suicide method on overall regional rates. J Epidemiol Community Health 2007;61:248–53.
- 2 Kuo CJ, Conwell Y, Yu Q, et al. Suicide by charcoal burning in Taiwan: implications for means substitution by a case-linkage study. Soc Psychiatry Psychiatr Epidemiol 2008;43:286–90.
- 3 Lin JJ, Lu TH. Suicide mortality trends by sex, age and method in Taiwan, 1971-2005. BMC Public Health 2008;8:6.
- 4 Pan YJ, Liao SC, Lee MB. Suicide by charcoal burning in Taiwan, 1995-2006. J Affect Disord 2010;120:254–7.
- 5 Cheng Q, Chang SS, Guo Y, et al. Information Accessibility of the Charcoal Burning Suicide Method in Mainland China. PLoS One 2015;10:e0140686.
- 6 Li F, Chan HC, Liu S, et al. Carbon monoxide poisoning as a cause of death in Wuhan, China: A retrospective six-year epidemiological study (2009-2014). Forensic Sci Int 2015;253:112–8.
- 7 Lu X, Li F, Chan Heng Choon (Oliver), et al. Carbon monoxide poisoning deaths in Shanghai, China: A 10-year epidemiological and comparative study with the Wuhan sample. Cogent Med 2016;3:1137131.
- 8 Choi YR, Cha ES, Chang SS, et al. Suicide from carbon monoxide poisoning in South Korea: 2006-2012. J Affect Disord 2014;167:322–5.
- 9 Yoshioka E, Saijo Y, Kawachi I. Spatial and temporal evolution of the epidemic of charcoal-burning suicide in Japan. *Soc Psychiatry Psychiatr Epidemiol* 2016;51:857–68.
- 10 Chang SS, Chen YY, Yip PS, et al. Regional changes in charcoal-burning suicide rates in East/Southeast Asia from 1995 to 2011: a time trend analysis. PLoS Med 2014;11:e1001622.
- 11 Thomas K, Chang SS, Gunnell D. Suicide epidemics: the impact of newly emerging methods on overall suicide rates - a time trends study. *BMC Public Health* 2011;11:314.
- 12 Schmitt MW, Williams TL, Woodard KR, et al. Trends in suicide by carbon monoxide inhalation in King County, Washington: 1996-2009. J Forensic Sci 2011;56:652–5.
- 13 Chen YY, Tsai CW, Biddle L, *et al*. Newspaper reporting and the emergence of charcoal burning suicide in Taiwan: A mixed methods approach. *J Affect Disord* 2016;193:355–61.
- 14 Ku CH, Hung HM, Leong WC, et al. Outcome of patients with carbon monoxide poisoning at a far-east poison center. PLoS One 2015;10:e0118995.
- 15 Bleecker ML. Carbon monoxide intoxication. Handb Clin Neurol 2015;131:191–203.
- 16 Taiwan Alzheimer's Disease Association. Expected Dementia popultion Report in Taiwan [web site]. 2015-2056;2013 http://www.tada2002.org.tw/tada_ know_02.html#01.
- 17 Fuh JL, Wang SJ. Dementia in Taiwan: past, present, and future. Acta Neurol Taiwan 2008;17:153–61.
- 18 Tzeng N-S, Chang C-W, Hsu J-Y, et al. Caregiver Burden for Patients with Dementia with or Without Hiring Foreign Health Aides: A Cross-Sectional Study in a Northern Taiwan Memory Clinic. Journal of Medical Sciences 2015;35:239–47.
- 19 Tzeng NS, Chiang WS, Chen SY, et al. The Impact of Pharmacological Treatments on Cognitive Function and Severity of Behavioral Symptoms in Geriatric Elder Patients with Dementia: Pharmacological Treatments on in Elder Patients with Dementia. *Taiwanese Journal Psychiatry*. In Press. 2017.
- 20 Wang HY, Chen JH, Huang SY, et al. Forensic Evaluations for Offenders With Dementia in Taiwan's Criminal Courts. J Am Acad Psychiatry Law 2018;46:45-51.
- 21 Lee YK, Hou SW, Lee CC, et al. Increased risk of dementia in patients with mild traumatic brain injury: a nationwide cohort study. PLoS One 2013;8:e62422.

- 22 Huang CY, Li YC, Wang HK, et al. Stroke suggests increased risk of dementia. Curr Alzheimer Res 2015;12:287-95.
- Tzeng NS, Chung CH, Lin FH, et al. Risk of Dementia in Adults With ADHD: 23 A Nationwide, Population-Based Cohort Study in Taiwan. J Atten Disord 2017:108705471771405.
- Golimstok A, Rojas JI, Romano M, et al. Previous adult attention-deficit and 24 hyperactivity disorder symptoms and risk of dementia with Lewy bodies: a case-control study. Eur J Neurol 2011;18:78-84.
- 25 Chen NC, Huang CW, Huang SH, et al. Cognitive severity-specific neuronal degenerative network in charcoal burning suicide-related carbon monoxide intoxication: a multimodality neuroimaging study in Taiwan. Medicine 2015;94:e783
- Ho Chan WS. Taiwan's healthcare report 2010. Epma J 2010;1:563-85. 26
- Chinese Hospital Association. ICD-9-CM English-Chinese Dictionary. Taipei, 27 Taiwan: Chinese Hospital Association Press 2000.
- 28 Ministry of Justice. National Health Insurance Reimbursement Regulations. web site] 2014. Available at http://law.moj.gov.tw/LawClass/LawAllIf.aspx?PCode= L0060006 (accessed 7 Mar 2018).
- Cheng CL, Chien HC, Lee CH, et al. Validity of in-hospital mortality data among 29 patients with acute myocardial infarction or stroke in National Health Insurance Research Database in Taiwan. Int J Cardiol 2015;201:96-101.
- 30 Lin CC, Lai MS, Syu CY, et al. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc 2005;104:157-63.
- 31 Liang JA, Sun LM, Muo CH, et al. The analysis of depression and subsequent cancer risk in Taiwan. Cancer Epidemiol Biomarkers Prev 2011;20:473-5.
- Li-Ting C, Chung-Ho C, Yi-Hsin Y, et al. The development and validation of oral cancer staging using administrative health data. BMC Cancer 2014;14:380.
- 33 Yang CC, Chen PC, Hsu CW, et al. Validity of the age-adjusted charlson comorbidity index on clinical outcomes for patients with nasopharyngeal cancer post radiation treatment: a 5-year nationwide cohort study. PLoS One 2015:10:e0117323.
- Cheng CL, Lee CH, Chen PS, et al. Validation of acute myocardial infarction 34 cases in the national health insurance research database in taiwan. J Epidemiol 2014:24:500-7
- Hsieh CY, Chen CH, Li CY, et al. Validating the diagnosis of acute ischemic 35 stroke in a National Health Insurance claims database. J Formos Med Assoc 2015:114:254-9
- Chou IC, Lin HC, Lin CC, et al. Tourette syndrome and risk of depression: a 36 population-based cohort study in Taiwan. J Dev Behav Pediatr 2013;34:181-5.
- 37 Cheng CL, Kao YH, Lin SJ, et al. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 2011;20:236-42.
- 38 Sung SF, Hsieh CY, Lin HJ, et al. Validity of a stroke severity index for administrative claims data research: a retrospective cohort study. BMC Health Serv Res 2016;16:509.
- 39 Sung SF, Hsieh CY, Lin HJ, et al. Validation of algorithms to identify stroke risk factors in patients with acute ischemic stroke, transient ischemic attack, or intracerebral hemorrhage in an administrative claims database. Int J Cardiol 2016;215:277-82.
- 40 Tseng HP, Lin FJ, Chen PT, et al. Derivation and validation of a discharge disposition predicting model after acute stroke. J Stroke Cerebrovasc Dis 2015;24:1179-86.
- Yang H, Chen YH, Hsieh TF, et al. Prediction of Mortality in Incident 41 Hemodialysis Patients: A Validation and Comparison of CHADS2, CHA2DS2, and CCI Scores. PLoS One 2016;11:e0154627.
- 42 Wu CS, Lai MS, Gau SS, et al. Concordance between patient self-reports and claims data on clinical diagnoses, medication use, and health system utilization in Taiwan. PLoS One 2014;9:e112257.
- Yu ST, Chang HY, Lin MC, et al. Agreement between self-reported and health insurance claims on utilization of health care: A population study. J Clin Epidemiol 2009;62:1316-22.

- Tzeng NS, Chung CH, Lin FH, et al. Headaches and Risk of Dementia. Am J Med Sci. In Press. 2017;353:197-206.
- Mehta HB, Mehta V, Tsai CL, et al. Development and Validation of the RxDx-45 Dementia Risk Index to Predict Dementia in Patients with Type 2 Diabetes and Hypertension. J Alzheimers Dis 2016;49:423-32.
- 46 Marzona I, Baviera M, Vannini T, et al. Risk of dementia and death in patients with atrial fibrillation: A competing risk analysis of a population-based cohort. Int J Cardiol 2016;220:440-4.
- 47 Blanche P, Proust-Lima C, Loubère L, et al. Quantifying and comparing dynamic predictive accuracy of joint models for longitudinal marker and time-to-event in presence of censoring and competing risks. Biometrics 2015:71:102-13.
- 48 Lai CY, Huang YW, Tseng CH, et al. Patients With Carbon Monoxide Poisoning and Subsequent Dementia: A Population-Based Cohort Study. Medicine 2016:95:e2418.
- 49 Wong CS, Lin YC, Hong LY, et al. Increased Long-Term Risk of Dementia in Patients With Carbon Monoxide Poisoning: A Population-Based Study. Medicine 2016;95:e2549.
- 50 Lin RT, Lai CL, Tai CT, et al. Prevalence and subtypes of dementia in southern Taiwan: impact of age, sex, education, and urbanization. J Neurol Sci 1998;160:67-75.
- 51 Sun Y, Lee HJ, Yang SC, et al. A nationwide survey of mild cognitive impairment and dementia, including very mild dementia, in Taiwan. PLoS One 2014;9:e100303.
- 52 Liu HC, Lin KN, Teng EL, et al. Prevalence and subtypes of dementia in Taiwan: a community survey of 5297 individuals. J Am Geriatr Soc 1995;43:144-9.
- Liu CK, Lai CL, Tai CT, et al. Incidence and subtypes of dementia in southern 53 Taiwan: impact of socio-demographic factors. Neurology 1998;50:1572-9.
- 54 Chen HL, Chen PC, Lu CH, et al. Structural and cognitive deficits in chronic carbon monoxide intoxication: a voxel-based morphometry study. BMC Neurol 2013:13:129
- 55 Mahmoud O, Mestour M, Loualidi M. [Carbon monoxide intoxication and anterograde amnesia]. Encephale 2009;35:281-5.
- 56 Buckley NA, Juurlink DN, Isbister G, et al. Hyperbaric oxygen for carbon monoxide poisoning. Cochrane Database Syst Rev 2011:CD002041.
- 57 Juurlink DN, Buckley NA, Stanbrook MB, et al. Hyperbaric oxygen for carbon monoxide poisoning. Cochrane Database Syst Rev 2005:CD002041.
- 58 Juurlink DN, Stanbrook MB, McGuigan MA. Hyperbaric oxygen for carbon monoxide poisoning. Cochrane Database Syst Rev 2000:CD002041.
- Chen YY, Chen F, Chang SS, et al. Assessing the Efficacy of Restricting Access 59 to Barbecue Charcoal for Suicide Prevention in Taiwan: A Community-Based Intervention Trial. PLoS One 2015;10:e0133809.
- 60 Gerhard T. Bias: considerations for research practice. Am J Health Syst Pharm 2008;65:2159-68.
- 61 Hitosugi M, Nagai T, Tokudome S. Proposal of new ICD code for suicide by charcoal burning. J Epidemiol Community Health 2009;63:862-3.
- 62 Lin JJ, Chen LH, Huang SM, et al. Problems in estimating the number of suicides by charcoal burning in Taiwan. J Epidemiol Community Health 2008;62:566.
- 63 Ministry of Health and Walfare. Statistics of suicide deaths over the years and statistics on suicide notifications in Taiwan [web site]. 2016 https://www. mohw.gov.tw/dl-40567-9a30a6f1-0e6f-4e7c-90b0-cf0503e89c58.html (accessed 21 Apr 2018).
- 64 Centre for Suicide Research and Prevention Hong Kong University. Method used in completed suicide in Hong Kong [web site]|. 2016 https://csrp.hku.hk/ statistics/ (accessed 21 Apr 2018).
- 65 Chen YY, Yip PS, Lee CK, et al. The diffusion of a new method of suicide: charcoal-burning suicide in Hong Kong and Taiwan. Soc Psychiatry Psychiatr Epidemiol 2015;50:227-36.